ProCE Banner Activity

Selecting the Right Proteasome Inhibitor for Your Patients With Multiple Myeloma

Clinical Thought
Now that 3 effective proteasome inhibitors are approved by the FDA for multiple myeloma, read how to select the optimal agent for your patients considering dosing, safety profiles, and efficacy in risk-defined subgroups.

Released: August 24, 2018

Expiration: August 23, 2019

No longer available for credit.

Share

Faculty

Noopur Raje

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Celgene

Takeda Oncology

Faculty Disclosure

Primary Author

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received consulting fees from Amgen, Celgene, Millennium, and Onyx.